Health Business

“Roche Pharma India partners with Cipla to create greater access to key medicines”

Lara-Bezerra-MD,-Roche-Phar

Roche Pharma India and Cipla announced today that the two companies have entered into an agreement under which Cipla will promote Actemra (tocilizumab) and the 2nd brand of Roche’s cancer therapy, Avastin (Bevacizumab). This partnership is in line with Roche’s efforts to improve healthcare and increase access to its innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.

Lara-Bezerra-MD,-Roche-Phar

  • Roche Products (India) Private Limited and Cipla Ltd have signed a distribution agreement for the promotion and sale of tocilizumab and the 2nd brand of bevacizumab.
  • Through this partnership, the companies will leverage their expertise to increase access to these innovative medicines for patients in India

Roche Pharma India and Cipla announced today that the two companies have entered into an agreement under which Cipla will promote and distribute tocilizumab (Actemra) and Syndyma, the 2nd brand of Roche’s cancer therapy, bevacizumab (Avastin) in India. This partnership is in line with Roche and Cipla’s efforts to improve healthcare and increase access to innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.

Lara Bezerra, Managing Director – Roche Pharma India said: “At Roche, improving access to the critical medicines that patients need is an integral part of what we do. We believe that everyone who needs our medicines should be able to access and benefit from them. This partnership will significantly advance our efforts to expand the reach of, and improve access to, our innovative medicines. This will also enable us at Roche to focus on bringing new, transformative medicines to patients in India. As Roche, we will continue to collaborate with various stakeholders to help transform healthcare in India.”

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top